Medicare Enrolled

Dr. John Case, M.D.

Urology Physician · San Antonio, TX
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
18915 MEISNER DR, San Antonio, TX 78258
2104995158
In practice since 2006 (19 years)
NPI: 1396859039 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Case from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Case? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Case

Dr. John Case is an urology physician in San Antonio, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Case performed 6,557 Medicare services across 3,945 unique beneficiaries.

Between the years covered by Open Payments, Dr. Case received a total of $2,877 from 31 pharmaceutical and/or device companies across 159 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Case is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 16% volume in TX $2,877 industry payments

Medicare Practice Summary

Medicare Utilization ↗
6,557
Medicare services
Top 16% in TX for urology physician
3,945
Unique beneficiaries
$54
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~345 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Infectious disease DNA/RNA test 1,009 $34 $78
Urinalysis with microscopic exam 796 $3 $15
Chronic care management, first 20 min/month 671 $40 $80
PSA test (prostate cancer screening) 636 $18 $110
Office visit, established patient (30-39 min) 531 $84 $215
Office visit, established patient (20-29 min) 376 $59 $150
Bladder ultrasound after voiding 356 $7 $95
Testosterone (hormone) level, total 353 $25 $150
Red blood cell concentration measurement 304 $2 $8
Blood count, hemoglobin 304 $2 $8
Placement of hormone pellet under skin 138 $62 $250
Unclassified drugs 137 $943 $1,238
Blood draw (venipuncture) 106 $8 $10
Diagnostic exam of bladder and urethra using an endoscope 99 $168 $490
Yeast/candida DNA test 83 $34 $78
Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique 83 $34 $78
Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique 83 $34 $78
New patient office visit (45-59 min) 78 $104 $313
New patient office visit (30-44 min) 70 $74 $210
Basic metabolic blood panel 51 $8 $45
Complete blood count (CBC) with differential 42 $7 $25
Psa (prostate specific antigen) measurement, free 36 $18 $150
Analysis for detection of tumor marker 36 $20 $115
Blood creatinine level 27 $5 $20
Urea nitrogen level to assess kidney function, quantitative 26 $4 $20
Ct scan of abdomen and pelvis before and after contrast 23 $255 $700
Initial hospital admission, moderate complexity 22 $100 $275
Hospital follow-up visit, low complexity 18 $38 $90
Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method 15 $125 $732
Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm 12 $136 $1,150
Complete laser vaporization of prostate including control of bleeding using an endoscope 12 $525 $2,875
Biopsy of prostate gland 12 $95 $350
Ultrasound scan of pelvic region through rectum 12 $25 $285
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$2,877
Total received (2018-2024)
Avg $411/year across 7 years
Bottom 47% in TX for urology physician
31
Companies
159
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,877 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$530
2023
$411
2022
$357
2021
$153
2020
$79
2019
$422
2018
$926

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Endo Pharmaceuticals Inc.
$382
Janssen Biotech, Inc.
$300
Astellas Pharma US Inc
$271
Sumitomo Pharma America, Inc.
$242
Blue Earth Diagnostics Limited
$201
PFIZER INC.
$137
Myovant Sciences Inc.
$128
AbbVie, Inc.
$116
Novartis Pharmaceuticals Corporation
$113
Dendreon Pharmaceuticals LLC
$96
Amgen Inc.
$95
UroGPO LLC
$88
TOLMAR Pharmaceuticals, Inc.
$85
Aytu BioScience, Inc
$76
Bayer HealthCare Pharmaceuticals Inc.
$65
Boston Scientific Corporation
$52
UroGen Pharma, Inc.
$50
Antares Pharma, Inc.
$49
Avadel Specialty Pharmaceuticals, LLC
$43
Medtronic, Inc.
$40
Myriad Genetic Laboratories, Inc.
$34
UROGEN PHARMA, INC.
$32
Allergan Inc.
$29
AstraZeneca Pharmaceuticals LP
$26
ABBVIE INC.
$21
Retrophin, Inc.
$21
Duchesnay USA Incorporated
$20
UROVANT SCIENCES INC
$20
Tolmar, Inc.
$20
Egalet US Inc
$13
Acerus Pharmaceuticals Corporation
$12
Top 3 companies account for 33.1% of total payments
Associated products mentioned in payments ›
(815) Thiola · AVEED · Androgel · Axumin · BOTOX · BOTOX THERAPEUTIC · DARZALEX · ELIGARD · ERLEADA · Erleada · GEMTESA · INTERSTIM · JELMYTO · LYNPARZA · LithoVue Empower · Lumenis Pulse 120H · Lupron · Lupron Depot · MYRBETRIQ · Myrbetriq · NURO · Natesto · Noctiva · Nubeqa · ORGOVYX · Osphena · Otrexup · PLUVICTO · POSLUMA · PREMARIN · PROLARIS · PROVENGE · Prolia · SPRIX · SUTENT · TOVIAZ · Tria Firm · Veozah · XIAFLEX · XTANDI · XYOSTED · Xofigo · Xtandi · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $44 per 100 Medicare services performed
Looking for an urology physician in San Antonio?
Compare urology physicians in the San Antonio area by procedure volume, costs, and industry payment transparency.
Browse urology physicians nearby

Geographic Context

Urology physicians within 10 mi
100
Per 100K population
4.9
County median income
$70,571
Nearest hospital
SOUTH TEXAS SPINE AND SURGICAL HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Case is a clinical cardiology specialist, with above-average Medicare volume (top 16% in TX), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Case experienced with infectious disease dna/rna test?
Based on Medicare claims data, Dr. Case performed 1,009 infectious disease dna/rna test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Case receive payments from pharmaceutical companies?
Yes. Dr. Case received a total of $2,877 from 31 companies across 159 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Case's costs compare to other urology physicians in San Antonio?
Dr. Case's average Medicare payment per service is $54. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Case) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →